Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Jean M Whaley, Mark Tirmenstein, Timothy P Reilly, Simon M Poucher, JoAnne Saye, Shamik Parikh & James F List. (2012) Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity 5, pages 135-148.
Read now
Read now
William N Washburn. (2012) Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents. Expert Opinion on Therapeutic Patents 22:5, pages 483-494.
Read now
Read now
Philip A Carpino & Bryan Goodwin. (2010) Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature. Expert Opinion on Therapeutic Patents 20:12, pages 1627-1651.
Read now
Read now
Thomas D Aicher, Steven A Boyd, Maralee McVean & Anthony Celeste. (2010) Novel therapeutics and targets for the treatment of diabetes. Expert Review of Clinical Pharmacology 3:2, pages 209-229.
Read now
Read now
Articles from other publishers (65)
琪 张. (2022) Study on the Pharmacological Effects of the Main Active Ingredients in the Seeds of “Guiyou No. 1” Pomelo on Diabetes. Botanical Research 11:03, pages 229-238.
Crossref
Crossref
Dana El Masri, Yasser Jamil & Jocelyne Eid Fares. (2022) Sodium-Glucose Co-Transporter Protein 2 Inhibitors Induced Hypercalcemia: A Case Series and Literature Review. AACE Clinical Case Reports 8:1, pages 30-33.
Crossref
Crossref
L.M. Kalynska & O.I. Kovzun. (2021) Вплив дапагліфлозину на активність ангіотензин-перетворюючого ферменту в структурах гіпоталамо-гіпофізарно- адренокортикальної системи та функцію кори надниркових залоз у щурів із цукровим діабетом 2-го типу. Endokrynologia 26:4, pages 357-365.
Crossref
Crossref
Мaryana М. Rоsul, Мiroslava М. Bletskan, Nataliya V. Ivano, Marina O. Korabelschykova & Yelyzaveta І. Rubtsova. (2020) PRIORITIES OF ANTI-HYPERGLYCAEMIC DRUG THERAPY IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE. Wiadomości Lekarskie 73:3, pages 609-613.
Crossref
Crossref
Stefan D. Anker & Javed Butler. (2018) Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle. ESC Heart Failure 5:4, pages 549-551.
Crossref
Crossref
Anderson R. Aguillón, Alessandra Mascarello, Natanael D. Segretti, Hatylas F. Z de Azevedo, Cristiano R. W. Guimaraes, Leandro S. M. Miranda & Rodrigo O. M. A. de Souza. (2018) Synthetic Strategies toward SGLT2 Inhibitors. Organic Process Research & Development 22:4, pages 467-488.
Crossref
Crossref
Anna Sadurní, Gerald Kehr, Marie Ahlqvist, Johan Wernevik, Helena Peilot Sjögren, Cecilia Kankkonen, Laurent Knerr & Ryan Gilmour. (2018) Fluorine-Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 Inhibitors for Type II Diabetes. Chemistry - A European Journal 24:12, pages 2832-2836.
Crossref
Crossref
Yao Li, Zongjun Shi, Lei Chen, Suxin Zheng, Sheng Li, Bo Xu, Zhenhong Liu, Jianyu Liu, Chongyang Deng & Fei Ye. (2017) Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry 60:10, pages 4173-4184.
Crossref
Crossref
Nicole C. Goodwin, Zhi-Ming Ding, Bryce A. Harrison, Eric D. Strobel, Angela L. Harris, Melinda Smith, Andrea Y. Thompson, Wendy Xiong, Faika Mseeh, Debra J. Bruce, Damaris Diaz, Suma Gopinathan, Ling Li, Emily O’Neill, Mary Thiel, Alan G. E. Wilson, Kenneth G. Carson, David R. Powell & David B. Rawlins. (2017) Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes. Journal of Medicinal Chemistry 60:2, pages 710-721.
Crossref
Crossref
S. Mishra, A.S. Singh, N. Mishra, H. Pandey & V.K. Tiwari. 2017. Discovery and Development of Antidiabetic Agents from Natural Products. Discovery and Development of Antidiabetic Agents from Natural Products
147
183
.
Yukihiro Bando, Hitomi Tohyama, Keiko Aoki, Hideo Kanehara, Azusa Hisada, Kazuhiro Okafuji & Daisyu Toya. (2016) Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus. Journal of Clinical & Translational Endocrinology 6, pages 1-7.
Crossref
Crossref
Prachi Gupta, Manju Bala, Sanjeev Gupta, Anita Dua, Rajesh Dabur, Elisha Injeti & Ashwani Mittal. (2016) Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs—A mechanistic revisit to understand their mode of action. Pharmacological Research 113, pages 636-674.
Crossref
Crossref
Preeti Arora, Rakesh Narang, Surendra Kumar Nayak, Sachin Kumar Singh & Vikramjeet Judge. (2016) 2,4-Disubstituted thiazoles as multitargated bioactive molecules. Medicinal Chemistry Research 25:9, pages 1717-1743.
Crossref
Crossref
Qi Yan, Ning Ding & Yingxia Li. (2016) Synthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors. Carbohydrate Research 421, pages 1-8.
Crossref
Crossref
Chiho Yamamoto, Hideaki Miyoshi, Kota Ono, Hajime Sugawara, Reina Kameda, Mei Ichiyama, Kohei Yamamoto, Hiroshi Nomoto, Akinobu Nakamura & Tatsuya Atsumi. (2016) Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocrine Journal 63:6, pages 589-596.
Crossref
Crossref
Toshiyuki Takasu, Shoji Takakura & Kaori Hamada. (2016) Visualization of mechanism of action, and a further therapeutic potential of ipragliflozin, a selective SGLT2 inhibitor. Folia Pharmacologica Japonica 148:5, pages 266-271.
Crossref
Crossref
Madhu Babu Tatina, Anil Kumar Kusunuru & Debaraj Mukherjee. (2015)
Organo-zinc Promoted Diastereoselective
C
-Arylation of 1,2-Anhydrosugars from Arylboronic Acids
. Organic Letters 17:18, pages 4624-4627.
Crossref
Crossref
Yuyang Ding, Liufeng Mao, Dengfeng Xu, Hui Xie, Ling Yang, Hongjiang Xu, Wenjun Geng, Yong Gao, Chunguang Xia, Xiquan Zhang, Qingyi Meng, Donghai Wu, Junling Zhao & Wenhui Hu. (2015) C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents. Bioorganic & Medicinal Chemistry Letters 25:14, pages 2744-2748.
Crossref
Crossref
Julian P. Henschke, Chen-Wei Lin, Ping-Yu Wu, Wen-Shing Tsao, Jyh-Hsiung Liao & Pei-Chen Chiang. (2015)
β-Selective
C
-Arylation of Diisobutylaluminum Hydride Modified 1,6-Anhydroglucose: Synthesis of Canagliflozin without Recourse to Conventional Protecting Groups
. The Journal of Organic Chemistry 80:10, pages 5189-5195.
Crossref
Crossref
John R. WhiteJrJr. (2015) Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. Annals of Pharmacotherapy 49:5, pages 582-598.
Crossref
Crossref
Julian P. Henschke, Ping-Yu Wu, Chen-Wei Lin, Shi-Feng Chen, Pei-Chen Chiang & Chi-Nung Hsiao. (2015)
β-Selective
C
-Arylation of Silyl Protected 1,6-Anhydroglucose with Arylalanes: The Synthesis of SGLT2 Inhibitors
. The Journal of Organic Chemistry 80:4, pages 2295-2309.
Crossref
Crossref
Toshiyuki Takasu, Shoji Takakura & Seiji Kaku. (2015) Pharmacological and clinical profile of ipragliflozin (Suglat®): a new therapeutic agent for type 2 diabetes. Folia Pharmacologica Japonica 145:1, pages 36-42.
Crossref
Crossref
Priyanka Malla, Rajnish Kumar, Manoj K. Mahapatra & Manoj Kumar. (2014) Ramping Glucosuria for Management of Type 2 Diabetes Mellitus: An Emerging Cynosure. Medicinal Research Reviews 34:6, pages 1146-1167.
Crossref
Crossref
Atsunori Kashiwagi, Kenichi Kazuta, Satoshi Yoshida & Itsuro Nagase. (2013) Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation 5:4, pages 382-391.
Crossref
Crossref
Timothy P. Reilly, Michael J. Graziano, Evan B. Janovitz, Thomas E. Dorr, Craig Fairchild, Francis Lee, Jian Chen, Tai Wong, Jean M. Whaley & Mark Tirmenstein. (2014) Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus. Diabetes Therapy 5:1, pages 73-96.
Crossref
Crossref
Vincent Mascitti & Ralph P. Robinson. 2014. Natural Products in Medicinal Chemistry. Natural Products in Medicinal Chemistry
301
332
.
Sumihiro Nomura, Yasuo Yamamoto, Yosuke Matsumura, Kiyomi Ohba, Shigeki Sakamaki, Hirotaka Kimata, Keiko Nakayama, Chiaki Kuriyama, Yasuaki Matsushita, Kiichiro Ueta & Minoru Tsuda-Tsukimoto. (2013)
Novel Indole-
N
-glucoside, TA-1887 As a Sodium Glucose Cotransporter 2 Inhibitor for Treatment of Type 2 Diabetes
. ACS Medicinal Chemistry Letters 5:1, pages 51-55.
Crossref
Crossref
Janet C. Gould, Sreeneeranj Kasichayanula, David C. Shepperly & David W. Boulton. (2013) Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2. Regulatory Toxicology and Pharmacology 67:1, pages 89-97.
Crossref
Crossref
Shawn Riser Taylor & Kira B. Harris. (2013) The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Type 2 Diabetes Mellitus. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:9, pages 984-999.
Crossref
Crossref
Eiji Kurosaki & Hideaki Ogasawara. (2013) Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data. Pharmacology & Therapeutics 139:1, pages 51-59.
Crossref
Crossref
Debbie Hinnen. (2013) The Role of the Kidney in Hyperglycemia. Journal of Cardiovascular Nursing 28:2, pages 157-165.
Crossref
Crossref
Brian Zambrowicz, Zhi-Ming Ding, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Joel Freiman, Melinda Smith, Dennis Ruff, Arthur Sands & David Powell. (2013) Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes. Clinical Therapeutics 35:3, pages 273-285.e7.
Crossref
Crossref
Vincent Mascitti, Benjamin A. Thuma, Aaron C. Smith, Ralph P. Robinson, Thomas Brandt, Amit S. Kalgutkar, Tristan S. Maurer, Brian Samas & Raman Sharma. (2013) On the importance of synthetic organic chemistry in drug discovery: reflections on the discovery of antidiabetic agent ertugliflozin. MedChemComm 4:1, pages 101-111.
Crossref
Crossref
Jürgen Sandow. 2013. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays
421
520
.
Kirti Kaul, Joanna M. Tarr, Shamim I. Ahmad, Eva M. Kohner & Rakesh Chibber. 2013. Diabetes. Diabetes
1
11
.
Nobuhiko Fushimi, Hideki Fujikura, Hiroaki Shiohara, Hirotaka Teranishi, Kazuo Shimizu, Shigeru Yonekubo, Kohsuke Ohno, Takashi Miyagi, Fumiaki Itoh, Toshihide Shibazaki, Masaki Tomae, Yukiko Ishikawa-Takemura, Takeshi Nakabayashi, Noboru Kamada, Tomonaga Ozawa, Susumu Kobayashi & Masayuki Isaji. (2012) Structure–activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia. Bioorganic & Medicinal Chemistry 20:22, pages 6598-6612.
Crossref
Crossref
Chun-Hsu Yao, Jen-Shin Song, Chiung-Tong Chen, Teng-Kuang Yeh, Tsung-Chih Hsieh, Szu-Huei Wu, Chung-Yu Huang, Yu-Lin Huang, Min-Hsien Wang, Yu-Wei Liu, Chi-Hui Tsai, Chidambaram Ramesh Kumar & Jinq-Chyi Lee. (2012) Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors. European Journal of Medicinal Chemistry 55, pages 32-38.
Crossref
Crossref
V Ia Shvarts. (2012) A new principle of the treatment of type 2 diabetes mellitus by stimulation of glucosuria. Problems of Endocrinology 58:4, pages 54-57.
Crossref
Crossref
B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh, D B Rawlins, N C Goodwin, R Mabon, B A Harrison, A Wilson, A Sands & D R Powell. (2012) LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial. Clinical Pharmacology & Therapeutics 92:2, pages 158-169.
Crossref
Crossref
G. Luippold, T. Klein, M. Mark & R. Grempler. (2012) Empagliflozin, a novel potent and selective SGLT‐2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin‐induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes, Obesity and Metabolism 14:7, pages 601-607.
Crossref
Crossref
Chunlei Tang, Xiaoyun Zhu, Dandan Huang, Xin Zan, Baowei Yang, Ying Li, Xiaoyong Du, Hai Qian & Wenlong Huang. (2011) A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Journal of Molecular Modeling 18:6, pages 2795-2804.
Crossref
Crossref
Shinji Sakuma, Shun Kanamitsu, Yumi Teraoka, Yoshie Masaoka, Makoto Kataoka, Shinji Yamashita, Yoshiyuki Shirasaka, Ikumi Tamai, Masahiro Muraoka, Yohji Nakatsuji, Toshiyuki Kida & Mitsuru Akashi. (2012)
Involvement of Functional Groups on the Surface of Carboxyl Group-Terminated Polyamidoamine Dendrimers Bearing Arbutin in Inhibition of Na
+
/Glucose Cotransporter 1 (SGLT1)-Mediated
d
-Glucose Uptake
. Molecular Pharmaceutics 9:4, pages 922-929.
Crossref
Crossref
E. J. Verspohl. (2012) Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes. Pharmacological Reviews 64:2, pages 188-237.
Crossref
Crossref
Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, Daisuke Yamajuku, Rumi Kihara, Yuka Hayashizaki, Toshiyuki Takasu, Masakazu Imamura, Li Qun, Hiroshi Tomiyama, Yoshinori Kobayashi, Atsushi Noda, Masao Sasamata & Masayuki Shibasaki. (2011) Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn-Schmiedeberg's Archives of Pharmacology 385:4, pages 423-436.
Crossref
Crossref
Betsy Dokken. (2012) The Kidney as a Treatment Target for Type 2 Diabetes. Diabetes Spectrum 25:1, pages 29-36.
Crossref
Crossref
Hsin-Yi Hung, Keduo Qian, Susan L. Morris-Natschke, Chau-Shin Hsu & Kuo-Hsiung Lee. (2012) Recent discovery of plant-derived anti-diabetic natural products. Natural Product Reports 29:5, pages 580.
Crossref
Crossref
Tristan S. Maurer, Avijit Ghosh, Nahor Haddish-Berhane, Aarti Sawant-Basak, Carine M. Boustany-Kari, Li She, Michael T. Leininger, Tong Zhu, Meera Tugnait, Xin Yang, Emi Kimoto, Vincent Mascitti & Ralph P. Robinson. (2011) Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology. The AAPS Journal 13:4, pages 576-584.
Crossref
Crossref
Timothy Colin Hardman & Simon William Dubrey. (2011) Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Therapy 2:3, pages 133-145.
Crossref
Crossref
S. Kasichayanula, X. Liu, W. Zhang, M. Pfister, S. B. Reele, A.-F. Aubry, F. P. LaCreta & D. W. Boulton. (2011) Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes, Obesity and Metabolism 13:8, pages 770-773.
Crossref
Crossref
Baihua Xu, Yan Feng, Huawei Cheng, Yanli Song, Binhua Lv, Yuelin Wu, Congna Wang, Shengbin Li, Min Xu, Jiyan Du, Kun Peng, Jiajia Dong, Wenbin Zhang, Ting Zhang, Liangcheng Zhu, Haifeng Ding, Zelin Sheng, Ajith Welihinda, Jacques Y. Roberge, Brian Seed & Yuanwei Chen. (2011) C-Aryl glucosides substituted at the 4′-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters 21:15, pages 4465-4470.
Crossref
Crossref
Vincent Mascitti, Tristan S. Maurer, Ralph P. Robinson, Jianwei Bian, Carine M. Boustany-Kari, Thomas Brandt, Benjamin M. Collman, Amit S. Kalgutkar, Michelle K. Klenotic, Michael T. Leininger, André Lowe, Robert J. Maguire, Victoria M. Masterson, Zhuang Miao, Emi Mukaiyama, Jigna D. Patel, John C. Pettersen, Cathy Préville, Brian Samas, Li She, Zhanna Sobol, Claire M. Steppan, Benjamin D. Stevens, Benjamin A. Thuma, Meera Tugnait, Dongxiang Zeng & Tong Zhu. (2011) Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors. Journal of Medicinal Chemistry 54:8, pages 2952-2960.
Crossref
Crossref
M Pfister, J M Whaley, L Zhang & J F List. (2011) Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus. Clinical Pharmacology & Therapeutics 89:4, pages 621-625.
Crossref
Crossref
Kwang-Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Junwon Lee, Sung-Han Lee, Myung Eun Jung, Eun-Jung Son, MinWoo Lee, Jeongmin Kim & Jinhwa Lee. (2010)
Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel
C
-Aryl Glucoside SGLT2 Inhibitors
. ACS Medicinal Chemistry Letters 2:2, pages 182-187.
Crossref
Crossref
Chun-Hsu YaoJen-Shin SongChiung-Tong ChenTeng-Kuang YehMing-Shiu HungChih-Chun ChangYu-Wei LiuMao-Chia YuanChieh-Jui HsiehChung-Yu HuangMin-Hsien WangChing-Hui ChiuTsung-Chih HsiehSzu-Huei WuWen-Chi HsiaoKuang-Feng ChuChi-Hui TsaiYu-Sheng ChaoJinq-Chyi Lee. (2010)
Discovery of Novel
N
-β-
d
-Xylosylindole Derivatives as Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Management of Hyperglycemia in Diabetes
. Journal of Medicinal Chemistry 54:1, pages 166-178.
Crossref
Crossref
Eun-Jung Park, Younggyu Kong, Jun Sung Lee, Sung-Han Lee & Jinhwa Lee. (2011) Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2. Bioorganic & Medicinal Chemistry Letters 21:2, pages 742-746.
Crossref
Crossref
Jiwen (Jim) Liu & TaeWeon Lee. 2011.
103
115
.
Rolf K. H. Kinne & Francisco Castaneda. 2011. Diabetes - Perspectives in Drug Therapy. Diabetes - Perspectives in Drug Therapy
105
126
.
Jian-Sung Wu, Yi-Hui Peng, Jiun-Ming Wu, Chieh-Jui Hsieh, Szu-Huei Wu, Mohane Selvaraj Coumar, Jen-Shin Song, Jinq-Chyi Lee, Chi-Hui Tsai, Chiung-Tong Chen, Yu-Wei Liu, Yu-Sheng Chao & Su-Ying Wu. (2010) Discovery of Non-Glycoside Sodium-Dependent Glucose Co-Transporter 2 (SGLT2) Inhibitors by Ligand-Based Virtual Screening. Journal of Medicinal Chemistry 53:24, pages 8770-8774.
Crossref
Crossref
Sumihiro Nomura, Shigeki Sakamaki, Mitsuya Hongu, Eiji Kawanishi, Yuichi Koga, Toshiaki Sakamoto, Yasuo Yamamoto, Kiichiro Ueta, Hirotaka Kimata, Keiko Nakayama & Minoru Tsuda-Tsukimoto. (2010)
Discovery of Canagliflozin, a Novel
C
-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
. Journal of Medicinal Chemistry 53:17, pages 6355-6360.
Crossref
Crossref
Vincent Mascitti & Cathy Préville. (2010) Stereoselective Synthesis of a Dioxa-bicyclo[3.2.1]octane SGLT2 Inhibitor. Organic Letters 12:13, pages 2940-2943.
Crossref
Crossref
Binhua Lv, Yan Feng, Jiajia Dong, Min Xu, Baihua Xu, Wenbin Zhang, Zelin Sheng, Ajith Welihinda, Brian Seed & Yuanwei Chen. (2010) Conformationally Constrained Spiro C-Arylglucosides as Potent and Selective Renal Sodium-Dependent Glucose Co-transporter 2 (SGLT2) Inhibitors. ChemMedChem 5:6, pages 827-831.
Crossref
Crossref
Hiroyuki Kakinuma, Takahiro Oi, Yuko Hashimoto-Tsuchiya, Masayuki Arai, Yasunori Kawakita, Yoshiki Fukasawa, Izumi Iida, Naoko Hagima, Hiroyuki Takeuchi, Yukihiro Chino, Jun Asami, Lisa Okumura-Kitajima, Fusayo Io, Daisuke Yamamoto, Noriyuki Miyata, Teisuke Takahashi, Saeko Uchida & Koji Yamamoto. (2010)
(1
S
)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-
d
-glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment
. Journal of Medicinal Chemistry 53:8, pages 3247-3261.
Crossref
Crossref
Huiqiang Zhou, Dana P. Danger, Steven T. Dock, Lora Hawley, Shane G. Roller, Chari D. Smith & Anthony L. Handlon. (2010)
Synthesis and SAR of Benzisothiazole- and Indolizine-β-
d
-glucopyranoside Inhibitors of SGLT2
. ACS Medicinal Chemistry Letters 1:1, pages 19-23.
Crossref
Crossref
Vincent Mascitti, Ralph P. Robinson, Cathy Préville, Benjamin A. Thuma, Christopher L. Carr, Matthew R. Reese, Robert J. Maguire, Michael T. Leininger, André Lowe & Claire M. Steppan. (2010) Syntheses of C-5-spirocyclic C-glycoside SGLT2 inhibitors. Tetrahedron Letters 51:14, pages 1880-1883.
Crossref
Crossref
Ralph P. Robinson, Vincent Mascitti, Carine M. Boustany-Kari, Christopher L. Carr, Patrick M. Foley, Emi Kimoto, Michael T. Leininger, Andre Lowe, Michelle K. Klenotic, James I. MacDonald, Robert J. Maguire, Victoria M. Masterson, Tristan S. Maurer, Zhuang Miao, Jigna D. Patel, Cathy Préville, Matthew R. Reese, Li She, Claire M. Steppan, Benjamin A. Thuma & Tong Zhu. (2010) C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization. Bioorganic & Medicinal Chemistry Letters 20:5, pages 1569-1572.
Crossref
Crossref